Disappointing 4Q for Amedisys - Analyst Blog

Date : 02/29/2012 @ 8:01AM
Source : Zacks
Stock : Amedisys (AMED)
Quote : 57.98  0.96 (1.68%) @ 4:24PM
Amedisys share price Chart

Disappointing 4Q for Amedisys - Analyst Blog

Home health care provider Amedisys (AMED) reported EPS of 25 cents in the fourth quarter of 2011, compared with 86 cents in the year-ago quarter. The company recorded goodwill impairment charge of $5.8 million during the quarter due to decline in market capitalization and disappointing performance over the past few quarters.

After taking into account this charge and other one-time expenses, the adjusted EPS in the reported quarter stood at 49 cents compared with $1.03 in the fourth quarter of 2010. The Zacks Consensus Estimate for the quarter was pegged at 29 cents. In fiscal 2011, the adjusted EPS from continuing operation came in at $2.27, down 50.8% year over year.

Amedisys primarily derives revenue from its home health and hospice agencies by providing a variety of services at homes. Net service revenue stood at $370.7 million in the reported quarter, almost in line with the Zacks Consensus Estimate but down 4.6% year over year.

The decline in net service revenue during the quarter was mainly due to a 14.3% drop in same-store Episodic-based sales. Net service revenue in fiscal 2011 was $1.5 billion, down 8.2% from $1.6 billion in the previous year.

Gross margin decreased 463 basis points (bps) to 45.19% in the fourth quarter of 2011. Adjusted operating margin (excluding the effect of depreciation and amortization, provision for doubtful accounts as well as goodwill and other intangibles impairment charge) witnessed a massive 530 bps year-over-year decline to 9.24%.

Amedisys exited the reported fiscal with cash and cash equivalents of $48.0 million, compared with $120.3 million at the end of December 2010.


Amedisys provided its guidance for fiscal 2012. The company expects EPS in the range of 95 cents–$1.10. The current Zacks Consensus Estimate of 95 cents falls at the lower end of the guided range. The company’s revenue guidance for 2012 is expected to remain within $1.475–$1.525 billion.

We believe the highly uncertain home nursing reimbursement environment (an expected reduction in Medicare reimbursements to hit the home health-care sector in another year) will further weaken the company’s persisting volatile position.

Presently, the stock retains a short-term Zacks #4 Rank (Sell). Over the long term, we have an Underperform recommendation on the company.

AMEDISYS INC (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

Amedisys (NASDAQ:AMED)
Historical Stock Chart

1 Year : From Feb 2017 to Feb 2018

Click Here for more Amedisys Charts.

Amedisys (NASDAQ:AMED)
Intraday Stock Chart

Today : Friday 23 February 2018

Click Here for more Amedisys Charts.

Latest AMED Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20180223 22:15:50